Literature DB >> 10652002

Epidermolysis bullosa: novel and de novo premature termination codon and deletion mutations in the plectin gene predict late-onset muscular dystrophy.

F Rouan1, L Pulkkinen, G Meneguzzi, S Laforgia, P Hyde, D U Kim, G Richard, J Uitto.   

Abstract

Epidermolysis bullosa (EB) with late-onset muscular dystrophy (EB-MD) is a hemidesmosomal variant of EB due to mutations in the plectin gene (PLEC1). The age of onset of muscle involvement has been noted to vary from infancy to the fourth decade of life. Immunofluorescence of the patients' skin and muscle biopsies is usually negative for staining with antibodies recognizing plectin, a large cytoskeleton-associated anchorage protein. In this study we report novel plectin mutations in two families with EB. In both families, the proband was a newborn with neonatal blistering with no evidence for muscle weakness as yet. Peripheral blood DNA was isolated and examined by heteroduplex scanning strategy, protein truncation test (PTT), and/or direct sequencing of the plectin gene. One of the probands was compound heterozygote for nonsense mutations E2005X/K4460X, and the proband in the second family was compound heterozygote for deletion mutations 5083delG/2745-9del21, the latter mutation extending from -9 to +12 at the intron 22/exon 23 border. The mutations K4460X and 5083delG were not present in either one of the parents, thus being de novo events. In both cases, nonpaternity was excluded by microsatellite marker analysis. The stop codon mutations are predicted to result in the synthesis of a truncated protein lacking the carboxy-terminal globular domain of the protein and possibly causing nonsense-mediated decay of the corresponding mRNA. The 2745-9del21 deletion mutation abolishes the splice site at the intron 22/exon 23 junction, predicting abnormal splicing events. Because plectin deficiency is associated with muscular dystrophy, molecular diagnostics of the plectin gene provides prognostic value in evaluation of these patients who appear to be at risk to develop muscular dystrophy.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10652002     DOI: 10.1046/j.1523-1747.2000.00880.x

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  6 in total

Review 1.  Epidermolysis bullosa simplex with muscular dystrophy. Review of the literature and a case report.

Authors:  Jana Kyrova; Lenka Kopeckova; Hana Buckova; Lenka Mrazova; Karel Vesely; Marketa Hermanova; Hana Oslejskova; Lenka Fajkusova
Journal:  J Dermatol Case Rep       Date:  2016-11-30

2.  A compound heterozygous one amino-acid insertion/nonsense mutation in the plectin gene causes epidermolysis bullosa simplex with plectin deficiency.

Authors:  J W Bauer; F Rouan; B Kofler; G A Rezniczek; I Kornacker; W Muss; R Hametner; A Klausegger; A Huber; G Pohla-Gubo; G Wiche; J Uitto; H Hintner
Journal:  Am J Pathol       Date:  2001-02       Impact factor: 4.307

3.  Myasthenic syndrome caused by plectinopathy.

Authors:  D Selcen; V C Juel; L D Hobson-Webb; E C Smith; D E Stickler; A V Bite; K Ohno; A G Engel
Journal:  Neurology       Date:  2011-01-25       Impact factor: 9.910

4.  Severe mucous membrane involvement in epidermolysis bullosa simplex with muscular dystrophy due to a novel plectin gene mutation.

Authors:  Ulrike Schara; Jens Tücke; Wilhelm Mortier; Thomas Nüsslein; Fatima Rouan; Ellen Pfendner; Detlef Zillikens; Leena Bruckner-Tuderman; Jouni Uitto; Gerhard Wiche; Rolf Schröder
Journal:  Eur J Pediatr       Date:  2004-02-13       Impact factor: 3.183

5.  Targeted ablation of plectin isoform 1 uncovers role of cytolinker proteins in leukocyte recruitment.

Authors:  Christina Abrahamsberg; Peter Fuchs; Selma Osmanagic-Myers; Irmgard Fischer; Friedrich Propst; Adelheid Elbe-Bürger; Gerhard Wiche
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-12       Impact factor: 11.205

6.  Phenotypic and molecular characteristics of androgen insensitivity syndrome patients.

Authors:  Shi-Min Yuan; Ya-Nan Zhang; Juan Du; Wen Li; Chao-Feng Tu; Lan-Lan Meng; Ge Lin; Guang-Xiu Lu; Yue-Qiu Tan
Journal:  Asian J Androl       Date:  2018 Sep-Oct       Impact factor: 3.285

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.